Remove 2018 Remove Chemotherapy Remove Immunization
article thumbnail

Unicorns Don’t Exist: Rethinking the Generalist Model in Oncology Pharmacy

Pharmacy Times

December 13, 2018. American Oncology Network. August 8, 2024. Accessed May 15, 2025. How your oncology peers manage the complexities of care. Oncology Live ®. Accessed May 15, 2025. Desimone R. Improve work performance with a focus on employee development. December 12, 2019. Updated January 19, 2024. Accessed May 15, 2025.

article thumbnail

FDA Approves Meloxicam Injection For Moderate-to-Severe Pain in Adults

Pharmacy Times

August 24, 2018. Additionally, like all NSAIDs, meloxicam injection should be used with caution in patients with cardiovascular, gastrointestinal, or renal risk factors. 2 REFERENCES 1. Schwenk E, Mariano E, et al. Designing the ideal perioperative pain management plan starts with multimodal analgesia. Korean Journal of Anesthesiology.

FDA 73
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

First CAR T-cell therapy recommended on NHS

European Pharmaceutical Review

Through the Cancer Drugs Fund (CDF), in 2018, England was the first European country to provide access to a CAR T-cell therapy to treat these blood cancers. Since then, over 500 patients in England have received axi-cel. CAR T-cell therapy engineers a patient’s own immune cells (T-cells) to detect, target and destroy cancer cells.

article thumbnail

Chemo-free regimen demonstrates efficacy in NSCLC

European Pharmaceutical Review

Janssen Pharmaceutical Companies of Johnson & Johnson’s Phase III MARIPOSA study is the first to show a clinically meaningful benefit in a chemotherapy-free regimen compared to the small molecule treatment TAGRISSO ® ( osimertinib ).

article thumbnail

NICE recommends first CAR-T cell therapy on NHS in England

pharmaphorum

More specifically, CAR-T cell therapy engineers a patient’s own immune cells (T-cells) to detect, target, and destroy cancer cells. After initial chemotherapy, up to 45% of patients with DLBCL will require a second line treatment, which often involves high-dose chemotherapy and a stem cell transplant.

article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

The development of novel radiotherapeutics ushered in a new era in targeted treatment 1 for cancer, with two separate radiotherapeutic approvals in Europe and the US, in 2018 and 2022. How do you perceive radiopharmaceuticals complementing existing cancer treatments, such as chemotherapy and immunotherapy?

article thumbnail

J&J backs out of $1.6bn blood cancer antibody alliance with Argenx

pharmaphorum

.” J&J paid Argenx a hefty $300 million upfront to secure rights to cusatuzumab (also known as JNJ-4550) in December 2018, and also made a $200 million equity investment in the Belgian company as part of a deal that had a total value of $1.6